Low-Dose naltrexone tested for long COVID fatigue

NCT ID NCT05430152

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether low-dose naltrexone (LDN) can reduce fatigue and improve related symptoms in people with post-COVID fatigue syndrome. 160 adults who had confirmed COVID-19 and met criteria for post-COVID fatigue took either LDN or a placebo for 16 weeks. The main goal was to see if LDN significantly lowered fatigue levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

low-dose naltrexone (LDN)

What this could lead to

If it works, this could offer a new treatment option for people suffering from long-lasting fatigue after COVID-19.

What could go wrong

This is a Phase 2 trial, so results are still early. The drug may not prove effective for everyone, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-VIRAL FATIGUE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Women's Health Research Institute

    Vancouver, British Columbia, V6H 3N1, Canada